Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

NCT07271121 is registered in ClinicalTrials.gov with King Hussein Cancer Center as lead sponsor.

NCT NCT07271121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07271121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
Lead sponsor
King Hussein Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
February 12, 2025
Completion date
June 30, 2028
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma refractory/ relapsed